Dr. Alice Bexon is a veteran of the pharmaceutical and biotech industry with over 20 years of experience and the owner of a consulting company called Bexon Clinical Consulting. She trained in the UK and then worked as an oncologist in France. Dr. Bexon has worked for co-operative groups, CROs, global pharmaceutical companies and biotech organizations. Along with a wide-ranging knowledge of clinical development and medical marketing, she has extensive experience of interacting with regulatory bodies such as the FDA and the EMA. Her team at Bexon Clinical Consulting of MDs, scientists and writers has extensive experience of writing and reviewing regulatory submissions worldwide.

Mark Alles is an accomplished executive in the biopharmaceutical industry who built and led highly successful global oncology-focused organizations and cancer therapeutics over his more than three-decade career. He is the former Chairman and Chief Executive Officer of Celgene Corporation, a global biopharmaceutical company, with an outstanding record of driving growth and medical innovation. During his 15-year tenure at Celgene, Mr. Alles executed several multi-billion-dollar company and asset acquisitions, developed a broad portfolio of globally marketed medicines and high-potential cancer therapeutics, and led the expansion of Celgene from a US-based organization of 500 employees to a global company with more than 8,800 employees serving patients around the world. Mr. Alles’ leadership at Celgene ultimately led to the company’s acquisition by Bristol Myers Squibb for $74 billion in late 2019. Prior to joining Celgene in 2004, he served as Vice President of the U.S. Oncology business unit at Aventis Pharmaceuticals, where he also held a series of executive management roles. He began his industry career at Bayer and Centocor prior to its acquisition by Johnson & Johnson. Mr. Alles is a recognized industry and community leader. He has served on the Boards of several biopharmaceutical companies and industry groups, including at Turning Point Therapeutics (acquired by Bristol Myers Squibb for $4.1B in 2022) where he served as Chair, the Pharmaceutical Research and Manufacturers of America (PhRMA), the European Federation of Pharmaceutical Industries and Associations (EFPIA), the Biotechnology Innovation Organization (BIO),  and he is a former member of the Trustees for the Healthcare Institute of New Jersey (HINJ). Currently, he is a member of the Board of Directors of multiple public and private biotechnology companies, including BioMarin Pharmaceutical, Syros Pharmaceuticals, PIKSci Inc, TORL BioTherapeutics, and Wugen Inc, and serves on the Board of Trustees for Misericordia University.

Professor Charlotte Deane MBE is currently a Professor of Structural Bioinformatics at the University of Oxford. Prof. Deane is a fellow of St Anne’s College and is Chief Scientific Officer – AI at Exscientia. Her research in the Oxford Protein Informatics Group (OPIG) covers several areas in protein structure and interaction networks, combining both theoretical and empirical analysis. With expertise in structural modeling, bioinformatics, and library design, her invaluable insights contribute to the advancement of machine learning algorithms in the field.

Dr. Todd Fehniger is a physician-scientist with over 25 years of experience in Immunology and Oncology. Dr. Fehniger is a Professor of Medicine at Washington University School of Medicine, Scientific Co-Director of the Center for Gene and Cellular Immunotherapy, and Co-Leader of the lymphoma program at the Siteman Cancer Center. Dr. Fehniger leads a research team focused on mechanisms of NK cell development and function, strategies to enhance immune responses to cancer, and lymphoma immunogenomics. His laboratory identified human memory NK cells differentiating after stimulation through combined cytokine receptors and pioneered translating NK cell memory as a cellular immunotherapy for leukemia. His clinical interests are hematologic malignancies, hematopoietic cell transplantation, and cellular immunotherapy.

Dr. Justin Gainor is the Director of the Center for Thoracic Cancers Program at the Massachusetts General Hospital (MGH), Director of Targeted Immunotherapy in the Henri and Belinda Termeer Center for Targeted Therapies, and Co-Leader of the SU2C Lung Cancer Dream Team. His major research interests have centered around two themes: targeted therapy and immunotherapy. Currently, he is the principal investigator of multiple clinical trials evaluating novel targeted therapies among patients with oncogene-driven lung cancers, with a particular focus on oncogenic fusions involving anaplastic lymphoma kinase (ALK) and RET. To complement these efforts, he has also led efforts to define the molecular mechanisms of resistance to targeted therapies.

Dr. Dennis Klinman is currently Chief Scientific Advisor at COBRO VENTURES, INC. He was trained in rheumatology and immunology. He spent 18 years at the FDA before moving to the NCI where he served as a Senior Investigator for 14 years. He holds several core patents in the field of TLR agonists, as well as for adjuvants such as those used in Heplisav (Hepatitis B vaccine) and the newest generation anthrax vaccine. His areas of expertise include immunotherapy, cancer vaccines, innate immunity, TLR agonists, autoimmunity and regulatory affairs.

Dr. Carl Novina is a serial entrepreneur and co-founder of AI Proteins, NextRNA Therapeutics, Dynamic Cell Therapies, and Microbial Machines. He is a Principal Investigator at the Dana-Farber Cancer Institute and Harvard Medical School and an Associate Member of the Broad Institute of Harvard and MIT.  His laboratory integrates basic science with development of advanced technologies to accelerate the translation of biological discoveries into novel therapies.

Dr. Eric Rowinsky has held numerous positions in the biopharmaceutical industry including Executive Vice President and Chief Medical Officer of ImClone Systems Incorporated, where he led the FDA approval of Erbitux® for head and neck and colorectal cancers and advanced eight other monoclonal antibodies through clinical development. He was also head of development or Head of Research and Development at Stemline Therapeutics, Inspirna (formerly Rgenix), and Stemline Therapeutics.   Dr. Rowinsky has also been an Adjunct Professor of Medicine at New York University School of Medicine and he sits on the boards of directors of Biogen Inc., Fortress Bio, Purple Bio, and Verastem Inc. Dr. Rowinsky held several positions at the Cancer Therapy and Research Center, including Director of the Institute of Drug Development, or IDD, and the SBC Endowed Chair for Early Drug Development at the IDD. He was a Clinical Professor of Medicine at the University of Texas Health Science Center at San Antonio. Dr. Rowinsky was an Associate Professor of Oncology at the Johns Hopkins University School of Medicine. He was a longstanding National Cancer Institute principal and co-principal investigator from 1990 to 2004 and was integrally involved in pivotal clinical and preclinical investigations that led to the development of numerous cancer therapeutics, including paclitaxel, docetaxel, topotecan, irinotecan, erlotinib, gefitinib and temsirolimus among others.

Dr. Robert Stein, an esteemed executive, is currently Executive Vice President, Research and Development at MIMEDX. With a strong academic background and extensive experience, he made significant contributions throughout his career. Notably, he played a key role in the FDA approvals of Sustiva, Innohep, and the blockbuster drug Eliquis. In various leadership positions, including President of Roche Palo Alto LLC and Chief Executive Officer of Kinemed, Dr. Stein demonstrated his expertise in Translational Medicine and Early Clinical Development. With a deep understanding of molecular and cellular biology, biochemistry, and drug metabolism, he led teams of over 1,000 scientists and physicians. Additionally, Dr. Stein serves on the boards of several companies and provides advisory services to clients and academic institutions, further cementing his influential presence in the field.

Dr. Omer Yilmaz is the Eisen and Chang Development Professor, Associate Professor of Biology at MIT, and board-certified anatomic pathologist at the Massachusetts General Hospital. He is also an Associate Member of the Broad Institute of Harvard and MIT and the Ragon Institute of MIT and Massachusetts General Hospital. Dr. Yilmaz’s laboratory studies how adult stem cells and their microenvironment adapt to various diets in the context of tissue regeneration, aging, and cancer initiation. His lab has also developed state-of-the-art preclinical models for studying colorectal cancer progression and metastasis.